XML 40 R23.htm IDEA: XBRL DOCUMENT
v3.22.1

Business Combination | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2022 | Dec. 31, 2021
Business Combinations [Abstract] |  |
BUSINESS COMBINATION | 17. BUSINESS COMBINATION On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, “Business Combination” to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey’s results of operations were included in the Company’s results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:
Purchase consideration: |  |  |
Common Stock (*) |  | $ | 44,341,847 |
Allocation of the purchase price: |  |  |  |
Cash and cash equivalents |  | $ | 531,147 |
Accounts receivable, net |  |  | 188,550 |
Property and equipment, net |  |  | 56,075 |
Operating lease right-of-use assets |  |  | 485,684 |
Security deposits |  |  | 10,440 |
Total assets acquired |  |  | 1,271,896 |
Accounts payable |  |  | (56,204 | )
Accrued expenses and other current liabilities |  |  | (251,335 | )
Operating lease liability |  |  | (267,256 | )
Tenant security deposit |  |  | (2,880 | )
Total liabilities assumed |  |  | (577,675 | )
Total net assets acquired |  |  | 694,221 |
Goodwill as a result of the Merger |  | $ | 43,647,626 |
| * | 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.
On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company’s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger. | 17. BUSINESS COMBINATION On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, “Business Combination” to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey’s results of operations were included in the Company’s results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:
Purchase consideration: |  |  |
Common Stock (*) |  | $ | 44,341,847 |
Allocation of the purchase price: |  |  |  |
Cash and cash equivalents |  | $ | 531,147 |
Accounts receivable, net |  |  | 188,550 |
Property and equipment, net |  |  | 56,075 |
Operating lease right-of-use assets |  |  | 485,684 |
Security deposits |  |  | 10,440 |
Total assets acquired |  |  | 1,271,896 |
Accounts payable |  |  | (56,204 | )
Accrued expenses and other current liabilities |  |  | (251,335 | )
Operating lease liability |  |  | (267,256 | )
Tenant security deposit |  |  | (2,880 | )
Total liabilities assumed |  |  | (577,675 | )
Total net assets acquired |  |  | 694,221 |
Goodwill as a result of the Merger |  | $ | 43,647,626 |
| * | 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.
On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company’s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI https://asc.fasb.org/topic&trid=2303972 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration